PYGL

Across TCGA pan-cancer cohorts, PYGL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PYGL data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher PYGL Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYGL expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SCLC, UCEC, and GBM are the cancer types where PYGL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.110	0.633	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.625	.009	16	view →
GBM	OS	Median	All	0.062	0.413	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LGG	OS	Median	All	0.317	0.799	.021	3	view →
LUAD	DFS	Median	II,III,IV	0.098	0.651	.001	3	view →
SKCM	DFS	Median	II,III,IV	0.962	0.681	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PYGL–SCLC (DFS)

Open the SCLC breakdown →